Comparative Pharmacology
Head-to-head clinical analysis: ARISTOCORT versus ARISTOSPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOCORT versus ARISTOSPAN.
ARISTOCORT vs ARISTOSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis; modulates gene expression and immune cell activity.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Intramuscular: 40-80 mg every 2-4 weeks; Intra-articular: 5-40 mg depending on joint size; Intralesional: 2.5-25 mg; Oral: 4-12 mg/day divided every 6-12 hours.
Triamcinolone hexacetonide (Aristospan) is administered intra-articularly or intralesionally. For intra-articular use in adults, typical dose is 2–20 mg (0.5–1 mL of 20 mg/mL suspension) depending on joint size. For intralesional use, 2–3 mg per injection site, with total dose not exceeding 0.5 mg/kg per day.
None Documented
None Documented
Plasma: 1-2 hours (triamcinolone); tissue half-life 18-36 hours due to receptor binding and slow release from tissues.
Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal elimination minor.
Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Category C
Category C
Corticosteroid
Corticosteroid